Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

Biogen Inc. (NASDAQ:BIIB ... I would like to begin with immunology where in collaboration with UCB, as Chris mentioned, we initiated the second Phase III study for dapi-pegol in SLE.

Biogen shares soared 44 percent on a single day ... ultimately failed to slow cognitive decline. Belgian biotech firm UCB SA is expected to decide whether to continue developing bepranemab ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB are planning a second late-stage trial by the end of the year to support a ...

UCB’s bepranemab slowed the accumulation of ... Semorinemab binds the N-terminal of tau, as did the now discontinued gosuranemab, from Biogen, tilavonemab, from AbbVie, and zagotenemab, from ...

Following the prior phase 2 study, Biogen, along with our collaboration partner, UCB, spent time analyzing the results in an attempt to design and derisk a phase 3 study and demonstrate a ...

Dr Dev Kumar, Partner, former GC of EUSA Pharma with expertise in IP and market access; Dr Kumar has worked at Biogen, UCB and BI and qualified as a medical doctor & lawyer. Dr Gary Whale ...